Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

Tens of millions of people worldwide live with HIV. Lenacapavir can prevent the virus for months with one injection — a ...

Tens of thousands of deaths and new HIV infections will be the direct result of Donald Trump’s abandonment of PEPFAR and ...